--- title: "Virax Biolabs Group Limited (VRAX.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/VRAX.US.md" symbol: "VRAX.US" name: "Virax Biolabs Group Limited" industry: "Health Care Distributors" datetime: "2026-05-19T09:46:55.461Z" locales: - [en](https://longbridge.com/en/quote/VRAX.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/VRAX.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/VRAX.US.md) --- # Virax Biolabs Group Limited (VRAX.US) ## Company Overview Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women’s health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. | Item | Detail | |------|--------| | Industry | Health Care Distributors | | Exchange | US Market | | Website | [viraxbiolabs.com](https://viraxbiolabs.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-19T04:30:12.000Z **Overall: D (0.68)** **Industry**: Health Care Distributors | Metric | Value | |--------|-------| | Industry Ranking | 16 / 16 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -96.48% | | | Net Profit YoY | 14.24% | | | P/B Ratio | 0.88 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 4682006.52 | | | Revenue | 2986.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -80.87% | E | | Profit Margin | -189001.71% | E | | Gross Margin | 80.10% | A | | Revenue YoY | -96.48% | E | | Net Profit YoY | 14.24% | C | | Total Assets YoY | -39.48% | E | | Net Assets YoY | -39.72% | E | | Cash Flow Margin | 95.78% | C | | OCF YoY | -96.48% | E | | Turnover | 0.00 | E | | Gearing Ratio | 11.23% | A | ```chart-data:radar { "title": "Longbridge Financial Score - Virax Biolabs Group Limited", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "-96.48%", "rating": "" }, { "name": "Net Profit YoY", "value": "14.24%", "rating": "" }, { "name": "P/B Ratio", "value": "0.88", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "4682006.52", "rating": "" }, { "name": "Revenue", "value": "2986.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "-80.87%", "rating": "E" }, { "name": "Profit Margin", "value": "-189001.71%", "rating": "E" }, { "name": "Gross Margin", "value": "80.10%", "rating": "A" }, { "name": "Revenue YoY", "value": "-96.48%", "rating": "E" }, { "name": "Net Profit YoY", "value": "14.24%", "rating": "C" }, { "name": "Total Assets YoY", "value": "-39.48%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-39.72%", "rating": "E" }, { "name": "Cash Flow Margin", "value": "95.78%", "rating": "C" }, { "name": "OCF YoY", "value": "-96.48%", "rating": "E" }, { "name": "Turnover", "value": "0.00", "rating": "E" }, { "name": "Gearing Ratio", "value": "11.23%", "rating": "A" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -0.83 | 10/16 | - | - | - | | PB | 0.88 | 4/16 | 0.55 | 0.46 | 0.31 | | PS (TTM) | 1567.99 | 13/16 | 760.74 | 503.93 | 348.05 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Henry Schein (HSIC.US) | B | C | A | D | B | B | | 02 | ZeroStack (ZSTK.US) | E | B | A | A | B | B | | 03 | McKesson (MCK.US) | E | B | A | E | B | C | | 04 | Cencora (COR.US) | B | B | A | E | C | C | | 05 | Cardinal Health (CAH.US) | E | C | A | E | B | C | ## Institutional View ### Analyst Rating Distribution > As of 2026-01-09T05:00:00.000Z Total Analysts: **1** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 1 | 100% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 0.23 | | Highest Target | 1.00 | | Lowest Target | 1.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VRAX.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VRAX.US/norm.md) - [Related News](https://longbridge.com/en/quote/VRAX.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VRAX.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**